|Stock Name : IPCA Laboratories Ltd /Tips Open||Buy : 2,054.00||Posted Date : Aug 25, 2020|
|Stopless/Horizon : 1900||Target : 2425||Results Achieved (Yes/No) :|
Overview: Ipca Laboratories limited is a fully integrated, pharmaceutical companyincorporated in the 1949. This company is a Mid Cap company with a market capital of Rs 25889.55.
About the company: Ipca manufactures formulations, active pharmaceutical ingredients (APIs), and drug intermediates. The company is one of the largest suppliers of APIs (atenolol, chloroquine and artemisinin derivatives, furosemide, and pyrantel salts) worldwide with manufacturing leadership in over 12 APIs globally. Ipca is a fully-integrated pharmaceutical company which manufactures over 350 formulations for various therapeutic segments.
Ipca’s product range includes pain management, cardiovascular medicines, anti-malarial, anti-emetic, antibiotic, analgesic, and anti-diabetic and formulations for cough and cold therapy, skin problems, and problems with the central nervous system.
Subsidiaries: Ipca Laboratories (UK) Ltd, Ipca Pharma (Australia) Pty. Ltd, Ipca Pharma (NZ) Pty. Ltd, Ipca Pharma Nigeria Ltd, Ipca Pharmaceuticals, Inc.USA, Pisgah Labs, Inc.USA, Bayshore Pharmaceuticals LLCUSA, Ipca Pharmaceuticals Ltd. SA de CV, Onyx Scientific Ltd.UK, and Tonira Exports Ltd., India.
Management: Mr. Premchand Godha is the Chairman & Managing Director and Mr. Pranay Godha& Mr. Prashant Godha are the Executive Director.
Shareholding Pattern (As on June 2020):
• Promoters: 46.07%
• ForeignInstitutions: 12.39%
• NBFC &MutualFunds: 22.82%
• CentralGovt: 0.16%
• Others: 2.78%
• GeneralPublic: 10.54%
• FinancialInstitutions: 5.24%
Dividend: Ipca Laboratories declared an equity dividend of 250.00% amounting to Rs 5 per share for the year ending March 2020.
Sales Report: For the quarter ended on 30th June 2020, Ipca reported a consolidated sale of Rs 1534.40 crore, which is up by 42.90 % from last quarter sales of Rs 1073.76 crore and up by 42.31 % from last year same quarter sales of Rs 1078.19 crore. Ipca Laboratories reported net profit after tax of Rs 446.75 Crore in latest quarter.
If you find any mistake please contact the firstname.lastname@example.org. This article is general in nature. It does not constitute a recommendation to buy and sell any stock, and does not take account of your objectives, or your financial situation. Largecapindia has no position in the stocks mentioned.
Largecapindia aim to bring you long term focused research analysis driven by fundamental thanks you.
For More Info : https://www.largecapindia.com